<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282838</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-15-CD-008</org_study_id>
    <nct_id>NCT03282838</nct_id>
  </id_info>
  <brief_title>Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects</brief_title>
  <official_title>Open-Label, Three Way, Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 Oral Solution Under Fasting Conditions vs Comparator Under Fed Conditions and to Determine Food Effect of DFN-15 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Three-Way Randomized, Single Dose Crossover Study Comparing Bioavailability of
      DFN-15 under fasting conditions versus Comparator under fed conditions and to determine
      food-effect of DFN-15 in Healthy Adult Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Actual">January 12, 2018</completion_date>
  <primary_completion_date type="Actual">August 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFN-15 maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DFN-15 area under the curve (AUC) 0-t</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DFN-15 area under the curve (AUC) 0-inf</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>DFN-15 (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 (fasted)</intervention_name>
    <description>DFN-15 administered to fasted subjects</description>
    <arm_group_label>DFN-15 (fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 (fed)</intervention_name>
    <description>DFN-15 administered to fed subjects</description>
    <arm_group_label>DFN-15 (fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator Celebrex® (fed)</intervention_name>
    <description>Comparator (Celebrex®) administered to fed subjects</description>
    <arm_group_label>Comparator (fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male or female 19-55 years of age, inclusive, at screening.

          -  Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or
             designee.

          -  Females of childbearing potential: must either be sexually inactive (abstinent) for 30
             days prior to the first dose and throughout the study or be using birth control
             method; Female subjects of non-childbearing potential and must have undergone
             sterilization procedures or be postmenopausal for at least 1 year prior

          -  Male subject must agree to use contraception or abstain during the study until 90 days
             beyond the last dose of study drug.

          -  Understands the study procedures in the informed consent form (ICF), and willing and
             able to comply with the protocol.

        Exclusion Criteria:

          -  History or presence of hypersensitivity or idiosyncratic reaction to celecoxib,
             sulfonamides, aspirin or other NSAIDs or related compounds

          -  History or presence of clinically significant medical or psychiatric condition or
             disease

          -  History of any illness that, in the opinion of the PI or designee, might confound the
             results of the study or poses an additional risk to the subject by their participation
             in the study

          -  liver enzyme tests greater than the upper limit of normal at screening

          -  Estimated creatinine clearance &lt;90 mL/minute at screening

          -  History or presence of alcoholism

          -  History or presence of bilateral pedal edema or generalized edema or fluid retention

          -  Female subjects who are pregnant or lactating or actively trying to conceive

          -  Positive urine drug or alcohol results at screening or check-in

          -  Positive cotinine at screening

          -  Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C virus (HCV)

          -  Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at screening

          -  Seated heart rate is lower than 45 bpm or higher than 100 bpm at screening

          -  Has been on a diet incompatible with the on-study diet

          -  Unable to refrain from or anticipates the use of prohibited medications

          -  Donation of blood or significant blood loss within 56 days prior to the first dose of
             study drug; plasma donation within 7 days prior to the first dose of study drug

          -  Participation in another clinical trial within 28 days prior to the first dose of
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

